In this podcast, expert clinicians will discuss the current tools for quantifying disease severity and burden in patients with gMG.

To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/neurology/20250220/1-understanding-disease-burden-and-severity-in-gmg

In this podcast, expert clinicians will discuss the pathophysiology of gMG and the significance of disease subtype on clinical decision-making. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/neurology/20250220/2-unraveling-the-pathophysiology-of-gmg-and-its-impact-on-treatment-selection

In this podcast, expert clinicians will discuss the latest clinical data on targeted therapies for management of patients with gMG. To claim CE credit after listening to this episode, go to this link and check the "Already listened on another platform?" box: https://healio.com/cme/mededtalks/neurology/20250220/3-exploring-the-latest-data-on-targeted-therapies-for-treating-gmg

In this podcast, expert clinicians will discuss the importance of patient-centered care in treatment decisions in Parkinson's disease.

In this podcast, expert clinicians will discuss the available and novel therapies for nonmotor symptoms associated with Parkinson's disease.

In this podcast, expert clinicians will discuss the current and emerging therapies for motor symptoms in Parkinson's disease.

In this podcast, expert clinicians will discuss the challenges in the staging and monitoring of Parkinson's disease.

In this podcast, expert clinicians will revisit an important topic from MS Forum® VIII, the use of current and emerging oral therapies for MS, including the Burton's tyrosine kinase (BTK) inhibitors.

In this podcast, expert clinicians will discuss gender-based Issues in MS and the role of patient-provider communication.

In this podcast, expert clinicians will discuss recent clinical evidence supporting optimal treatment selection for patients with progressive MS.